

6-1-40-1-10-20171205.pdf

By Radiyati Partan

Telmisartan Prevents Myocardial Fibrosis via Decreasing Fraction of Collagen Type 1 Volume in Myocardial Tissue in Wistar Rats-Induced High Salt Intake

Radiyah Umi Partan¹, Rachmat Hidayat^{2#}, Mgs Irsan Saleh³, Nita Parisa³, Nia Savitri³, Evi Lusiana³, Debby Handayati Harahap³, Ayeshah A Rosdah³, Muhammad Reagen¹

¹ Department of Internal Medicine, Faculty of Medicine, Sriwijaya University, Indonesia

² Biomolecular Laboratory, Faculty of Medicine, Sriwijaya University, Indonesia

³ Department of Pharmacology, Faculty of Medicine, Sriwijaya University, Indonesia

Correspondance Author : dr.rachmat.hidayat@gmail.com

Received : July 19th 2017

Accepted : September 19th 2017

Abstract

Myocardial fibrosis is a pathological condition that responsible for initiation of heart failure. Neurohormonal endogen, angiotensin II, has a potential role to activate endothelin I, TGF- β 1, myocardial fibroblast, extracelullar matrix deposition, structural changes and decreasing of cardiac function. Fibrotic process is also influenced by PPAR γ . Telmisartan has a potential effect to inactivate angiotensinergic system and to activate PPAR γ . It is expected that telmisartan has optimal effect to protect myocardial fibrosis. To know the role of variation dose of telmisartan to decrease collagen type 1 fraction volume in cardiac tissue of Wistar rats.

Ten-week-old male Wistar Rat (n = 30) were randomized into five groups, and each group consisted of 6 rats. Group 1 : negative control. Group 2 : rats were induced by intake Nacl 8% doses 2% body weight for eight weeks. Group 3 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 3 mg/kgBB for eight weeks. Group 4 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 6 mg/kgBB for eight weeks. Group 5 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 12 mg/kgBB for eight weeks. Collagen volume fraction was assessed by immunohistochemistry and ImageJ program. ANOVA test followed pos hoc test was used to analyzed each variable.

Collagen volume fraction significantly decreased in group 3, 4 and 5 compared in group 2. Telmisartan decreases collagen type 1 volume fraction of myocardial tissue .

Keywords : Telmisartan-Myocardial Fibrosis-Colagen Type 1-Rat-High Salt

Introduction

Myocardial fibrosis is a pathological condition that underlies the occurrence of heart failure.¹⁻⁴ Endogenous neurohormonal, angiotensin II, plays a role in endothelin activation I and transforming growth factor- β 1 (TGF- β 1), leading to the activation of myocardial fibroblasts. Myocardial fibroblasts will produce collagen which will form an

extracellular matrix so that there will be extracellular matrix deposition, structural changes and decreased heart function.⁵⁻¹¹

The fibrosis process is also affected by the peroxisome proliferator activated receptor (PPAR) subunit γ . Some lipid derivatives, particularly unsaturated fatty acids, are ligands of this receptor.^{12,13}

PPAR γ is expressed primarily on adipose tissue, which plays a role in improving insulin sensitivity. PPAR γ agonists are clinically used in the management of diabetes mellitus and metabolic syndrome.¹⁴ PPAR γ is also found in various organs including the heart and kidneys.^{15,16} PPAR γ plays a role in cellular differentiation, tumor cell antiproliferation activity and miofibroblasts.¹⁷ Activation of PPAR γ will Prevents bonding between the p-300 protein and the Smad protein, thus inhibiting the activation of myocardial fibroblasts.¹⁸ In addition, PPAR γ will prevent the association of the Smad3 protein (R-Smad) with response element and Co-Smad protein and thus inhibit the production of TGF- β 1.¹⁹

Telmisartan is an angiotensin I receptor blocker (ARB) which is useful as an anti-hypertensive drug and is identified as partial agonist PPAR γ .^{20,21} Related to activity on PPAR γ , telmisartan is believed to play a role in inflammatory response, malignancy management and management of cardiovascular disorders. This study aims to look at myocardial cardioprotective effects associated with myocardial fibrosis by assessing the fraction of collagen type 1 volume in the hearts of wistar rats.

Methods

Male Wistar rats, 10 weeks of age and body weight between 150-200g, were obtained from Laboratorium Penelitian dan Pengujian Terpadu (LPPT) Universitas Gadjah Mada (UGM) Yogyakarta. This research activity has received ethical approval from LPPT UGM ethics committee. Male Wistar rats (n = 30) performed randomization into five groups, each group of 6 rats. Group 1: negative control. Group 2: NaCl 8% given 2% weight for 8 weeks and aquades 5 ml. Group 3: NaCl 8% given dose 2% body weight and telmisartan 3 mg / kgBW, group 4: given 8% NaCl 2% dose 2% body weight and telmisartan 6 mg / kgBW and group 5: given 8% NaCl 2% dose body weight And telmisartan 12 mg / kgBW for 8 weeks. Every week, systolic blood pressure is measured with tail-cuff detection.²²

Rats performed anesthetized with ketamine (75mg / kgBB intraperitoneal). The organs of the heart was immediately isolated from the chest cavity and left ventricular heart removal was performed. The left ventricle was inserted in a 10% formalin solution for examination of collagen volume fractions.²² The tissue was made of paraffin block preparations. Made of 5 μ m thick slices, deparafinization, peroxidase blocking, retrieval antigen, non-specific binding blocking, IHC staining proper with anti-collagen type 1 antibody, staining with DAB, counterstain, dehydration and mounting. Collagen volume fraction was assessed with the help of the imageJ program. Each preparation preparation taken 15 field of view with magnification 40x.²²

The results of the analysis were shown as mean \pm SEM. Systolic blood pressure, weight and heart weight were compared between groups with ANOVA assay followed by post hoc (bonferroni test). The mean of collagen volume fraction was compared between groups with ANOVA assay followed by post hoc (Bonferroni test). The difference was statistically significant when p <0.05.

Results

Heart Weight

Heart weight showed significant differences between treatment groups (Group 1: 590 ± 1.78 ; Group 2: 648 ± 0.98 ; Group 3: 641 ± 1.50 ; Group 4: 636 ± 1.91 ; Group 5: 612 ± 1.25 ; $p = 0.00$). As shown in table 1.

Table 1. Heart Weight

No.	Group	Heart Weight (mg/100 gram BW)* (Mean \pm SEM)
1.	1	$590 \pm 1,78$
2.	2	$648 \pm 0,98$
3.	3	$641 \pm 1,50$
4.	4	$636 \pm 1,91$
5.	5	$612 \pm 1,25$

* P <0.05 ANOVA test

Systolic Blood Pressure

Systolic blood pressure before treatment showed no significant difference between groups (Graph 1). After 8 weeks treatment, systolic blood pressure did not show a significant increase in group 1 (negative control), but increased in the other group. Increased blood pressure significantly occurred in group 2 who received high intake of sodium compared to other groups. Telmisartan significantly lowered systolic blood pressure in groups of 3, 4 and 5 when compared to group 2 ($p = 0.00$).

Table 2. Systolic Blood Pressure

group	Systolic Blood Pressure (mmHg) (Mean \pm SEM)								
	start	Week I	Week II	Week III	Week IV	Week V	Week VI	Week VII	Week VIII
1	$115,83 \pm 0,9$	$116 \pm 1,05$	$116,29 \pm 0,8$	$115,62 \pm 0,8$	$120,92 \pm 0,3$	$119,33 \pm 0,6$	$120,13 \pm 0,5$	$119,71 \pm 0,4$	$119,88 \pm 0,2$
2	0	$124,75 \pm 1,0$	$135,33 \pm 1,6$	$125,50 \pm 0,6$	$136,50 \pm 3,4$	6	7	6	8
3	$116 \pm 0,59$	6	$120,75 \pm 0,6$	$119,75 \pm 0,4$	$128,62 \pm 0,9$	$141,62 \pm 3,2$	$142,50 \pm 3,0$	$146,67 \pm 2,4$	$162,75 \pm 2,2$
4	$115,79 \pm 0,7$	$115,33 \pm 0,5$	$117,79 \pm 0,5$	$115,62 \pm 1,2$	$124,92 \pm 1,7$	3	7	7	7
5	4	6	$114,58 \pm 0,9$	$106,25 \pm 1,2$	$117,46 \pm 1,2$	$129,96 \pm 0,7$	$129,46 \pm 1,7$	$133,17 \pm 1,1$	$136,71 \pm 1,0$
	$116,54 \pm 1,1$	$110,42 \pm 0,6$				8	6	2	1
	8	2				$124,29 \pm 0,8$	$122,54 \pm 0,9$	$126,16 \pm 0,5$	$128,71 \pm 0,5$
	$115,45 \pm 1,6$	$103,1 \pm 1,20$				6	1	5	6
	7					$113,12 \pm 1,9$	$116,17 \pm 1,5$	$116,67 \pm 2,2$	$117,21 \pm 2,0$
						9	0	3	0




Figure 1. Systolic Blood Pressure

Fraction of Collagen Type 1 Volume

Table 3 showed the mean fraction of collagen volume of experimental animals of group 1,2,3,4 and group 5. Based on one-way ANOVA test there was a significant difference between group 1,2,3,4 and group 5. Post hoc test, A significant difference between group 1 and group 2, $p = 0.00$. These results indicate an average difference in fraction volume of collagen between groups not receiving 8% sodium chloride supplementation and 8% sodium chloride group. Based on post hoc test, there were significant differences between group 2 and group 3,4 and 5. These results showed that there was a significant difference between the telmisartan and telmisartan group of 3 mg / kgBW, 6 mg / kgBW and 12 mg / KgBW.

Table 3. Fraction of Collagen Type 1 Volume

No.	Group	Fraction of Collagen Volume (%) (<i>Mean ± SEM</i>)
1.	1	30,05 ± 0,19
2.	2	34,45 ± 0,57
3.	3	30,22 ± 0,79
4.	4	26,24 ± 0,56
5.	5	19,47 ± 1,38








figure 2. Immunohistochemistry of Collagen Type 1 in Myocardial Tissue (400x)

1: group of animals that did not receive sodium chloride or telmisartan intake. 2: group of animals receiving sodium chloride 8% dose 2% animal body weight and aquadest 5 mL. 3: group of animals receiving sodium chloride 8% dose 2% body weight and telmisartan dose 3 mg / kgBW. 4: group of animals receiving sodium chloride 8% dose 2% body weight and telmisartan dose 6 mg / kgBW. 5: group of animals receiving sodium chloride 8% dose 2% body weight and telmisartan dose 12 mg / kgBW. White arrow : Collagen Type 1

Discussion

(High salt intake) sodium chloride 8% caused increasing in systolic blood pressure and caused myocardial fibrosis. Sodium chloride 8% administration will initiate the occurrence of myocardial fibrosis and kidney glomerulus, which is associated with increased expression of TGF- β 1.²² Telmisartan is an ARB class of antihypertensive drugs (angiotensin-I Receptor Blocker) and has been identified as ligands of PPAR (peroxisome proliferator activator receptor) γ .³ PPAR (peroxisome proliferator activator receptor) will lead to the formation of the complex PPAR, RE and NCoR that would inhibit TGF- β 1.²³⁻²⁶ The expression of PPAR γ will also prevent the binding between the protein p-300 with Smad proteins, thus preventing the recruitment of transcription factors that play a role in the activation miofibroblast.²⁷⁻³³ Miofibroblas has a major role in the process of accumulation of collagen.

This study showed that administration of telmisartan dose of 3 mg / kg, 6 mg / kg and 12 mg / kg body weight may prevent the accumulation of collagen in the myocardial tissue in animals that received sodium chloride 8%. The results of this study are in accordance with the research which states that telmisartan may slow the occurrence of fibrosis in the heart of rats with left ventricular hypertrophy.^{34, 35} The role of telmisartan administration a dose of 3 mg / kg, 6 mg / kg and 12 mg / kg in lowering the fraction of collagen volume and accumulation of collagen in the myocardial tissue.

Conclusion

Collagen volume fraction significantly decreased in group 3, 4 and 5 compared in group 2. Telmisartan decreases collagen type 1 volume fraction of myocardial tissue .

Acknowledgments

The study was supported by Sriwijaya Reseach Foundation from Sriwijaya University. Special thank to Maisha Pusrita for assistance in immunohistochemistry collagen type 1.

References

1. Carver W, Terracio L, Borg TK. Expression and accumulation of interstitial collagen in the neonatal rat heart. *Anat Rec.* 1993; 236:511-20.
2. Querejeta J, Lopez B, Gonzalez A, Sanchez E, Larman M, Ubago JL, Diez J. Increased collagen type 2 synthesis in patients with heart failure of hypertensive origin. *Circulation* 2004;110 : 1263-8.
3. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ modulating act¹⁴. *Hypertension.* 2004; 43:993–1002.
4. Eghbali M, Weber KT. Collagen and the myocardium: Fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. *Mol Cell Biochem.* 1990; 96: 1-14.

5. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The miofibroblas: one function, multiple origins. *Am J Pathol.* 2007; 170: 1807-16.
6. Kann TA. Cellular and molecular mechanisms of fibrosis. *J Pathol.* 2008; 214: 199-210.
7. Massague J. TGF-beta signal transduction. *Annu Rev Biochem.* 1998;67:753-91.
8. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. *FASEB J.* 2004; 18:816 - 27.
9. Roberts AB. TGF-beta signaling from receptors to the nucleus. *Microbes Infect.* 1999;1:1265-73.
10. Santander C, Brandan E. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. *Cell Signal.* 2006;18:1482-91.
11. Liu S, Shi-wen X, Kennedy L, Pala D, Carter DE, Black CM, Abraham DJ, Leask A. FAK is required for TGF-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix remodeling phenotype. *Mol Biol Cell.* 2007;18:2169 -78.
12. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM, Thomas PE. Miofibroblas differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. *J Biol Chem.* 2003;278:12384 -89.
13. Shi-wen X, Parapuram SK, Pala D, Chen Y, Carter D, Eastwood M, Abraham DJ, Leask A. TGF-induced-smooth muscle actin expression and extracellular matrix contraction in fibroblasts requires TAK1. *Arthritis Rheum.* 2009;60:234 -41.
14. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. *Circulation.* 2007;115:518-33.
15. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. *Circ Res.* 2011;108:1002-16.
16. B.R. Goyal, P. Mesariya, R.K. Goyal, A.A. Mehta, Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. *Mol. Cell Biochem.* 314 ; 2008: 123-31.
17. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell.* 1992; 68: 879 - 87.
18. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature.* 1990 ; 347: 645- 50.
19. Michalik L, Wahli W. PPARs mediate lipid signalling in inflammation and cancer. *PPAR Res.* 2008 ;1340-59.
20. Rotman, Nicholas, Wahli, Walter. PPAR modulation of kinase-linked receptor signaling in physiology and disease. *Physiology.* 2010; 25: 176-85.
21. Gressner OA, Lahme B, Rehbein K, Siluschek M, Vaskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. *J Hepatol.* 2008 ; 49: 758 -67.
22. S. Yamagishi, M. Takeuchi, Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. *Med. Hypotheses.* 2005; 64: 476-78.
23. I. Imayama, T. Ichiki, K. Inaga, H. Ohtsubo, K. Fukuyama, H. Ono, Y. Hashiguchi, K. Sunagawa, Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. *Cardiovasc. Res.* 2006; 72: 184-90.
24. Yu, Henry C.M., Burrell, Louise M., Black, M. Jane, Wu, Leonard L., Dilley, Rodney J., Cooper, Mark E. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. *Circulation.* 1998; 100: 2621-28.
25. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. *Diabetes.* 2004; 53:200-8.
26. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor gamma (PPAR-gamma)/Smad signalling pathways in human liver cancer cells. A novel mechanism for subversion of TGF beta-induced mitogenic inhibition. *J Biol Chem.* 2004; 279: 44344 - 54.
27. Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, Yabe-Nishimura C, Kim JH, Seo HG. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. *Circulation.* 2008;102: 193-200.
28. Kim HJ, Kim MY, Ji H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG. Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-beta1/Smad3. *Circ Res.* 2009;105: 16 - 24.

29. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Prog Lipid Res.* 2006;45: 120 – 59.
 30. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, Chen YE. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. *J Biol Chem.* 2001 ; 276: 10888 – 94.
 31. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signalling on epidermal growth factor receptor transactivation. *J Biol Chem.* 2003; 278: 46261– 69.
 32. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signalling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. *Arthritis Rheum.* 2004;50: 1305–18.
 33. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. *FASEB J.* 2009; 23: 2968 – 77.
 34. Zhang GY, Cheng T, Zheng MH, Yi CG, Peng H, Li ZJ, Chen XL, Yu Q, Jiang LF, Zhou FY, Li XY, Yang JQ, Chu TG, Gao WY. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. *Arch Dermatol Res* 2009; 301: 515–22.
 35. Widharto P, Hidayat R. Telmisartan Prevents Myocardial Fibrosis : Telmisartan Decreases TGF-β1 and Collagen Fraction Volume Myocardial Tissue in Wistar Rats Induced High Salt Intake. *Int J Biol Med Res.* 2015;6(3):5050-54.
-

22%

SIMILARITY INDEX

PRIMARY SOURCES

- 1 Epa, Amali Prasadini. "The Role of Cellular Cross-Talk in Regulating Human Lung Fibroblast to Myofibroblast Differentiation.", Proquest, 2016. 91 words — 3%
ProQuest
- 2 Goyal, Bhoomika R.. "Effect of spironolactone and telmisartan on cardiovascular complications.", Proquest, 2015. 86 words — 3%
ProQuest
- 3 Coleman, Jeffrey David. "Roles of peroxisome proliferator-activated receptorbeta/delta and B-cell lymphoma 6 in pancreatic cancer", Proquest, 20111108 67 words — 2%
ProQuest
- 4 Jones, Jennifer A. "Towards cell-specific therapy for restenosis: CCN5 in development and vascular injury", Proquest, 20111108 66 words — 2%
ProQuest
- 5 Varkey, Mathew. "Development of Novel Non-Scarring Tissue Engineered Skin to Treat Burn Patients and Others with Extensive Skin Loss.", Proquest, 2014. 63 words — 2%
ProQuest
- 6 Nakanishi, Masako. "The impact of prostaglandin suppression on intestinal tumorigenesis", Proquest, 20111004 53 words — 2%
ProQuest
- 7 Willis, William L.. "YB-1 Stress-Response Protein Conformation Implicated in Post-transcriptional Control of Myofibroblast Differentiation.", Proquest, 2015. 49 words — 2%
ProQuest

-
- 8 Cheang, Wai San. "Therapeutic Approaches Targeting Endoplasmic Reticulum Stress in Diabetic Endothelial Dysfunction.", Proquest, 2014. 42 words — 1%
- ProQuest
-
- 9 Borland, Michael Gregory. "Peroxisome proliferator-activated receptor beta/delta modulates aryl hydrocarbon receptor-dependent signaling and skin carcinogenesis.", Proquest, 2014. 34 words — 1%
- ProQuest
-
- 10 Dalrymple, Heidi Vanessa Claire. "Exploring pathways of lung homeostasis: Role of alveolar macrophages and lymphocytes", Proquest, 20111004 32 words — 1%
- ProQuest
-
- 11 Lin, Shuo-Yen Jack. "Structural and Functional Characterization of the Betaglycan Zona Pellucida Region and its Interaction with the TGF-beta Ligand Inhibin", Proquest, 20111108 23 words — 1%
- ProQuest
-
- 12 Bullock, Nia Joyner. "Maternal diabetes as it affects extracellular matrix deposition in the embryonic mouse heart", Proquest, 20111109 20 words — 1%
- ProQuest
-
- 13 Mousa, Ahm. "Epigenetic regulation of genes involved in vascular dysfunction in preeclamptic women", Proquest, 2013. 19 words — 1%
- ProQuest
-
- 14 Tong, W. "The Effect of Maternal Hypoxia on the Cerebral and Cardiac Tissue Remodeling", Proquest, 2014. 19 words — 1%
- ProQuest
-
- 15 Bennett, Christopher. "A Minority within a Minority: Identity and Well Being amongst Gay Men with Learning Disabilities.", University of Surrey (United Kingdom), 2003 16 words — 1%
- ProQuest

16 Smith, Russell William, III. "Therapeutic Potential of Ligand-Activated Peroxisome Proliferator-Activated Receptor beta/delta in Pancreatic Cancer.", The Pennsylvania State University, 2018 14 words — < 1%
ProQuest

17 Sharma, Vikas. "The Role of Bx42 in Dpp Signalling in the Early Drosophila Embryo.", The University of Manchester (United Kingdom), 2003 9 words — < 1%
ProQuest

18 Shen, Wei. "The role of inflammation in skeletal muscle healing", Proquest, 20111109 6 words — < 1%
ProQuest

EXCLUDE QUOTES OFF
EXCLUDE BIBLIOGRAPHY OFF

EXCLUDE MATCHES OFF